CSV April 4, 2023 through April 4, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TELMISARTAN PERFORMANC	*Revision*	Online		28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Flow rate*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AND HYDROCHLOROTHIAZIDE TABLETS	E TESTS/ *Dissolution <711>/Test 1/ Chromatographic system*	*Bulletin (Official February 01, 2018)*						Change The flow rate goes back to 0.6 mL to: The flow rate goes back to 0.6 mL/min
OLEYL OLEATE	CHEMICAL INFORMATION	*USP41–NF36*	5471	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change 532.92 to: 532.94
HOMATROPINE HYDROBROMIDE	*Limit of tropine*	*USP41–NF36*	2038	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Tropine reference solution*: Change 0.4 mg per mL. to: 0.4 mg per mL in *Diluent*.
TRIAZOLAM TABLETS	*Uniformity of dosage units <905>*	*USP41–NF36*	4202	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Mobile phase* and *Chromatographic system*: Change Proceed as directed in the *Assay* under *Triazolam*. to: Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed in the *Assay*. AND In *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Triazolam*. to: Proceed as directed in the *Assay*.
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in *Analysis*: Change C_U = nominal concentration of the *Sample solution* (mg/mL) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = nominal concentration of the *Sample solution* (mg/mL) [Note—Disregard any peak less than 0.1%.]
CUPRIC CHLORIDE	ASSAY/ *Procedure*	*USP41–NF36*	1109	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Analysis*: Change To the *Sample solution* to: To 50 mL of the *Sample solution*
AZEOTROPIC ISOPROPYL ALCOHOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2257	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and 2-butanol.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1%), diisopropyl ether (0.1%), 1-propanol (0.1%), 2-butanol (0.1%), and isopropyl alcohol (99.5%).
AMLODIPINE AND ATORVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$) AND In *Tolerances*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
LIDOCAINE	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the new *USP-NF*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ONLINE platform only. Line 2 of *Standard solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of *Sample solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid,
ALLOPURINOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	121	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 3 of USP Allopurinol Related Compound A RS: Change $(C_5H_6N_4O)_2 \cdot H_2SO_4$ 350.32 to: $(C_4H_6N_4O)_2 \cdot H$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{2}SO_4$ 350.31

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE PROPIONATE INHALATION POWDER	IMPURITIES/*Organic Impurities/System suitability*	*USP41–NF36*	1836	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Tailing factor*: Change NLT 1.3 to: NMT 1.3
AMLODIPINE AND ATORVASTATIN TABLETS	DEFINITION	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 4: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
OCTOCRYLENE	SPECIFIC TESTS/*Acidity*	*First Supplement to USP41–NF36*	8379	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Acceptance criteria*: Change NMT 0.18 mL of *Titrant* is required to: NMT 0.18 mL of *Titrant*/g is required
CUPRIC CHLORIDE INJECTION	ASSAY/*Procedure*	*USP41–NF36*	1111	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 3 of *Sample solution*: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								content of this flask to 13.5 mg.
METOPROLOL TARTRATE	CHEMICAL INFORMATION	*USP41–NF36*	2712	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 4: Change (±)-1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol l-(+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol (2:1) *dextro*-tartrate salt to: (±)-1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol (+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[4-(2-methoxyethyl)phen

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxy]propan-2-ol L-tartrate
ACAMPROSATE CALCIUM	IMPURITIES/*Limit of Acamprosate Related Compound A*	*First Supplement to USP41–NF36*	8263	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of USP Acamprosate Calcium Related Compound A RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Acamprosate Related Compound A RS in the *Standard solution* (µg/mL)
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								www.uspnf.com only. In *System suitability*: Add [Note—The relative retention times for oxybutynin and oxybutynin related compound A are about 1.0 and 1.6, respectively.]
CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION	IMPURITIES	*USP41–NF36*	951	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list of *Ciprofloxacin Related Compounds/Analysis*: Change C_U = nominal concentration of ciprofloxacin in the Otic Suspension (mg/mL) to: C_U = nominal concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ciprofloxacin in the *Sample solution* (mg/mL) AND In the variable definition list of *Dexamethasone Related Compounds/Analysis*: Change C_U = nominal concentration of dexamethasone in the Otic Suspension (mg/mL) to: C_U = nominal concentration of dexamethasone in the *Sample solution* (mg/mL)
GLUTARAL CONCENTRATE	ASSAY/ *Procedure*	*USP41–NF36*	1960	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change *W* = weight of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Concentrate taken (g) to: *W* = nominal weight of glutaral taken (g)
AMLODIPINE AND ATORVASTATIN TABLETS	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 8*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of oxybutynin chloride in the *Standard solution* (mg/mL) to: C_S = concentration of USP Oxybutynin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chloride RS in the *Standard solution* (mg/mL)
CUPRIC SULFATE INJECTION	*Assay*	*USP41–NF36*	1112	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 8 of *Assay preparation*: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg.
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution Test 1*	*USP41–NF36*	3157	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times V \times (100/L)$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times V \times (100/L) \times D$ AND In the variable definition list in *Analysis*: Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								D = dilution factor for the *Sample solution*, 2
NAPROXEN SODIUM TABLETS	IM PURITIES/*Organic Impurities*	*First Supplement to USP41–NF36*	8363	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *System suitability solution*: Change 0.5 mg/mL of USP Naproxen Sodium RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*, respectively to: 0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sodium RS in *Diluent*
RIZATRIPTAN BENZOATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	3662	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 6 of USP Rizatriptan Benzoate System Suitability Mixture RS: Change 269.34) to: 269.35)
STERILE WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
ZOLMITRIPTAN TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2017)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of *Analysis*: Change *Sample*: *Sample solution* to: *Samples*: *Standard solution* and *Sample solution*
LEVODOPA	IMPURITIES/*Organic*	*USP41–NF36*	2392	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Footnote a of *Table 1*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							3-(3,4,6-Trihydroxyphenyl)alanine. to: 3-(3,4,6-Trihydroxyphenyl)alanine; also known as 3-(2,4,5-Trihydroxyphenyl)-L-alanine.
WATER FOR HEMODIALYSIS	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4348	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	1447	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of USP Ethinyl Estradiol Related Compound B RS: Change 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{20}H_{22}O_2$ 294.39 to: 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol monohydrate. $C_{20}H_{22}O_2 \cdot H_2O$ 312.40
VINORELBINE INJECTION	ASSAY/ *Procedure/System suitability/Suitability requirements*	*USP41–NF36*	4326	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Relative standard deviation*: Change NLT 2.0%, *Standard solution* to: NMT 2.0%, *Standard solution*
STERILE WATER FOR IRRIGATION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
RITONAVIR CAPSULES	PERFORMANCE TESTS/	*Revision Bulletin (Official April 01, 2018)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Row 1 of Column 3 of *Table 1*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Dissolution <711>/Test 2							Change *Tolerances (Q)* to: *Tolerances* AND Row 3 of Column 3 of *Table 1*: Change NLT 80% to: NLT 80% (*Q*)
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE ACETATE OPHTHALMIC SUSPENSION	*Assay for hydrocortisone acetate*	*USP41–NF36*	2904	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1: Change Proceed with Ophthalmic Suspension as directed in the *Assay* under *Hydrocortisone Acetate Injectable Suspension*. to: *Standard prep aration*—Prepare as directed for *Assay for Steroids <351>*, *Standard Preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								using USP Hydrocortisone Acetate RS. *Assay prep aration* —Transfer to a separator an accurately measured volume of Ophthalmic Suspension, equivalent to about 50 mg of hydrocortisone acetate, and dilute with water to about 15 mL. Extract with four 25-mL portions of chloroform, filtering each portion through chloroform-washed cotton into a 250-mL volumetric flask. Add chloroform to volume, and mix. Pipet 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of this solution into a 100-mL volumetric flask, add chloroform to volume, and mix. Pipet 10 mL of the resulting solution into a gl ass-stoppered, 50-mL conical flask, evaporate the chloroform on a steam bath just to dryness, cool, and dissolve the residue in 20.0 mL of alcohol. *Proce dure*—Proceed as directed for *Assay for Steroids* <*351*>, *Procedure*. Calculate the quantity, in mg, of hydrocortisone acetate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{23}H_{32}O_6$) in each mL of Ophthalmic Suspension taken by the formula: $5(C/V)(A_U/A_S)$ in which V is the volume, in mL, of Ophthalmic Suspension taken; and the other terms are defined therein.
STERILE WATER FOR INHALATION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
PURE STEAM	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4348	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
GUAIFENESIN	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2001	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the equation in *Analysis*: Change Result = $(r_U/r_S) \times (1/F) \times 100$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Result = (r_U/r_S) × (C_S/C_U) × (1/F) × 100 AND Add to the variable list: C_S = concentration of guaifenesin in the *Diluted sample solution* C_U = concentration of guaifenesin in the *Sample solution*
WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
AMOXICILLIN	IDENTIFICATION/*A.*	*First Supplement to*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to*	This erratum applies to the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
		USP41–NF36					*USP41–NF36*	new *USP-NF* ONLINE platform only. Line 1: Change *Infrared Absorption <197>* to: *Infrared Absorption <197K>*
MEPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2580	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of Bupivacaine Related Compound B: Change *N*-(2,6-Dimethylphenyl)piperidine-2-carboxamide. $C_{14}H_{20}N_2O$ 232.32 to: *N*-(2,6-Dimethylphenyl)piperidine-2-carboxamide hydrochloride. $C_{14}H_{20}N_2O \cdot HCl$ 268.79
TEST FOR	PROCEDURES	*USP41–NF36*	6108	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
1,6-ANHYDRO DERIVATIVE FOR ENOXAPARIN SODIUM	/*Procedure*						*Supplement to USP41–NF36*	*Reduction suitability test*: Change 0.02%. to: 0.02.
LIDOCAINE	IM PUR ITIES/*Heavy Metals <231>*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *Acceptance criteria*: Change NMT 20 ppm ?1S *(USP41)* to: NMT 20 ppm ?(Official 1-Jan-2018)
TRIAMTERENE	IM PUR ITIES/*Organic Impurities*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *Standard stock solution 2*: Change 0.1 mg/mL of in *Diluent*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.1 mg/mL of USP Triamterene Related Compound A RS in *Diluent*. AND Line 1 of *Standard stock solution 3*: Change 0.1 mg/mL of USP Tranylcypromine Related Compound B RS in *Diluent*. to: 0.1 mg/mL of USP Triamterene Related Compound B RS in *Diluent*.
ISOPROPYL ISOSTEARATE	ADDITIONAL REQUIREMENTS	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 2 of *USP Reference Standards*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LORAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2474	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	<*11*>: Change USP Isostearyl Isostearate RS to: USP Isopropyl Isostearate RS Line 3 of USP Lorazepam Related Compound B RS: Change 266.13 to: 266.12 AND Line 4 of USP Lorazepam Related Compound C RS: Change 303.15 to: 303.14 AND Line 4 of USP Lorazepam Related Compound D RS: Change 319.15 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PIOGLITAZONE AND GLIMEPIRIDE TABLETS	IMPURITIES/*Organic Impurities: Glimepiride*	*USP41–NF36*	3314	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	319.14 Change *Table 3* to: *Table 4* AND Change *Table 4* to: *Table 5* AND Line 1 of *Mobile phase*: Change *Table 3* to: *Table 4* AND In the variable definition list in *Analysis*: Change *F* = relative response factor for each impurity (see *Table 4*) to: *F* = relative response factor for each impurity (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Table 5) AND Line 1 of *Acceptance criteria*: Change *Table 4* to: *Table 5*
BUMETANIDE TABLETS	IM PUR ITIES/*Organic Impuri ties/ Chromatographi c system*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Developing solvent system*: Change Methanol, cyclohexane, methanol, glacial acetic acid, and chloroform (2.5: 10: 10: 80) to: Methanol, cyclohexane, glacial acetic acid, and chloroform (2.5: 10: 10: 80)
TRANYLCYPR OMINE TABLETS	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change *Mobile phase*: *Methanol* and *Buffer* (30:70) *Diluent*: *Methanol*, water, and 0.05 N sulfuric acid ? VS?1S *(USP41)* (20:60:20) to: *Mobile phase*: *Methanol* and *Buffer* (30:70) ? ?(ERR 1-Oct-2018) *Diluent*: *Methanol*, water, and 0.05 N sulfuric acid ? VS?1S *(USP41)* (20:60:20)

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 14
- Page 15
- Page 16
- Page 17

- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- …
- Next page Next ›
- Last page Last »